What Is the Utility of KDIGO Criteria to Identify High-Risk Populations?

Affiliations

¹ Division of Nephrology, Department of Medicine, University Hospital Würzburg, Würzburg, Germany. Electronic address: wanner_c@ukw.de.
² Division of Nephrology, Department of Medicine, University Hospital Würzburg, Würzburg, Germany.

Editorial

Christoph Wanner et al. Am J Kidney Dis. 2021 Jan.

. 2021 Jan;77(1):7-8.

doi: 10.1053/j.ajkd.2020.10.002.

¹ Division of Nephrology, Department of Medicine, University Hospital Würzburg, Würzburg, Germany. Electronic address: wanner_c@ukw.de.
² Division of Nephrology, Department of Medicine, University Hospital Würzburg, Würzburg, Germany.

No abstract available

Comment on

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Blais J, Li Q, Jardine MJ, Perkovic V, Wheeler DC. Neuen BL, et al. Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. doi: 10.1053/j.ajkd.2020.06.018. Epub 2020 Sep 21. Am J Kidney Dis. 2021. PMID: 32971190 Clinical Trial.